Plain-English translation of NCT05004987 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research examines whether the antidepressant escitalopram can help reduce Alzheimer's disease risk by studying changes in brain and blood markers. Depression and Alzheimer's disease are connected in ways scientists don't fully understand, so this trial treats depression and measures whether this treatment also improves biological signs associated with Alzheimer's disease.
Depression may increase the risk of developing Alzheimer's disease, but doctors don't know if treating depression could help prevent or slow Alzheimer's. This study explores whether reducing depression symptoms with this medication might normalize the biological changes linked to Alzheimer's.
You likely qualify if…
You likely don't qualify if…
You would take either the antidepressant medication or a placebo (a pill with no active ingredient) daily for the study period. You would visit the research clinic multiple times for physical exams, memory tests, blood draws, brain imaging, and a spinal tap to measure Alzheimer's-related markers. The study team monitors your depression symptoms and overall health throughout the trial to see if the medication affects the biological signs linked to Alzheimer's disease.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States